Results of a Randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients

被引:69
|
作者
Cahn-Weiner, DA
Malloy, PF
Rebok, GW
Ott, BR
机构
[1] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA
[2] Mem Hosp Rhode Isl, Pawtucket, RI USA
[3] Butler Hosp, Providence, RI 02906 USA
[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[5] Brown Med Sch, Dept Clin Neurosci, Providence, RI USA
来源
APPLIED NEUROPSYCHOLOGY | 2003年 / 10卷 / 04期
关键词
memory training; Alzheimer's Disease; randomized placebo-controlled;
D O I
10.1207/s15324826an1004_3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The efficacy of a memory-training program to improve word-list recall and recognition was evaluated in 34 patients with probable Alzheimer's disease (AD). The patients, who were all taking donepezil throughout the 6-week intervention, were randomly assigned to a cognitive intervention group or a control group. The Control group received didactic presentations but no formal memory training. Patients were assessed on neuropsychological tests before the 6-week training program, immediately after the training, and 8 weeks after completion of the training. Caregivers, who were blind to group assignment, completed activities of daily living (ADLs) and everyday memory questionnaires at all three timepoints. No significant main effects of group (training vs. control) or time were observed on any outcome measures, nor were any significant interactions found. In terms of "process" measures during the 6-week training program, the patients demonstrated modest improvement on recall and recognition of test material presented during the training sessions. These results suggest that although modest gains in learning and memory may be evident in AD patients who are taught specific strategies, the benefits do not generalize to other measures of neuropsychological functioning after a brief intervention.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 50 条
  • [21] Cognitive training in Alzheimer's disease: a controlled randomized study
    Giovagnoli, A. R.
    Manfredi, V.
    Parente, A.
    Schifano, L.
    Oliveri, S.
    Avanzini, G.
    NEUROLOGICAL SCIENCES, 2017, 38 (08) : 1485 - 1493
  • [22] Cognitive training in Alzheimer’s disease: a controlled randomized study
    A. R. Giovagnoli
    V. Manfredi
    A. Parente
    L. Schifano
    S. Oliveri
    G. Avanzini
    Neurological Sciences, 2017, 38 : 1485 - 1493
  • [23] No Evidence of Intelligence Improvement After Working Memory Training: A Randomized, Placebo-Controlled Study
    Redick, Thomas S.
    Shipstead, Zach
    Harrison, Tyler L.
    Hicks, Kenny L.
    Fried, David E.
    Hambrick, David Z.
    Kane, Michael J.
    Engle, Randall W.
    JOURNAL OF EXPERIMENTAL PSYCHOLOGY-GENERAL, 2013, 142 (02) : 359 - 379
  • [24] The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
    Rogers, SL
    Friedhoff, LT
    Apter, JT
    Richter, RW
    Hartford, JT
    Walshe, TM
    Baumel, B
    Linden, RD
    Kinney, FC
    Doody, RS
    Borison, RL
    Ahem, GL
    DEMENTIA, 1996, 7 (06): : 293 - 303
  • [25] A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease
    Wong, WJ
    Liu, HC
    Fuh, JL
    Wang, SJ
    Hsu, LC
    Wang, PN
    Sheng, WY
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (04) : 289 - 294
  • [26] A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease
    Petracca, GM
    Chemerinski, E
    Starkstein, SE
    INTERNATIONAL PSYCHOGERIATRICS, 2001, 13 (02) : 233 - 240
  • [27] Randomized placebo-controlled trial of zonisamide in patients with Parkinson's disease
    Murata, Miho
    Hasegawa, Kazuko
    Kanazawa, Ichiro
    Shirakura, Kenji
    Kochi, Kenji
    Shimazu, Rieko
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2016, 4 (01): : 10 - 15
  • [28] A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease
    Petracca, G
    Teson, A
    Chemerinski, E
    Leiguarda, R
    Starkstein, SE
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 1996, 8 (03) : 270 - 275
  • [29] Safety and Efficacy of Methylphenidate for Apathy in Alzheimer's Disease: A Randomized, Placebo-Controlled Trial
    Rosenberg, Paul B.
    Lanctot, Krista L.
    Drye, Lea T.
    Herrmann, Nathan
    Scherer, Roberta W.
    Bachman, David L.
    Mintzer, Jacobo E.
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (08) : 810 - 816
  • [30] Safety of Intravenous Immunoglobulin (IGIV) Therapy in Patients with Probable Alzheimer's Disease (AD): a Randomized, Placebo-Controlled Clinical Study
    Gelmont, David
    Thomas, Ronald G.
    Dyck-Jones, Jacqueline A.
    Fritsch, Sandor
    Aisen, Paul
    Relkin, Norman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 : S53 - S54